Immunotherapy in Hematological Malignancies

Immunotherapy in Hematological Malignancies
Elsevier CME Independent Conference Highlights of the ASH 2017* Annual Meeting

This is a CME-accredited Elsevier Conference Reporter webcast based on a virtual roundtable discussion on immunotherapy in hematological malignancies. During the discussion three key opinion leaders summarize and give their expert opinion on important data from abstracts presented at the American Society of Hematology (ASH) 2017 Annual Meeting. The webcast lasts approximately 1 hour.

*This webcast is not endorsed by the conference organizer. Elsevier Office of Continuing Medical Education is an independent medical education company that provides clinical updates, analysis, and expert perspectives through conference coverage educational programs.


This activity has been designed to meet the educational needs of a broad audience including oncologists, hematologists, pathologists, pediatricians and other HCPs responsible for the diagnosis, treatment, or management of patients with hematological malignancies.


After viewing this activity, participants will be better able to:

  1. Review the mode of actions of various immunotherapies and explain why these can be effective in hematological malignancies
  2. Analyze the clinical trial data on immunotherapies for the treatment of hematological malignancies presented at the ASH 2017 Annual Meeting
  3. Develop data-driven, individualized treatment plans that include immunotherapies to improve clinical outcomes for patients with hematological malignancies, including lessons learned from the use of immunotherapies in solid tumors


Ian Flinn, MD
Sarah Cannon Research Institute
Nashville, TN, USA
Daniel D. DeAngelo, MD, PhD
Dana-Farber Cancer Institute
Boston, MA, USA
Mitchell R. Smith, MD, PhD
George Washington University Cancer Center
Washington, DC, USA

Disclosure of Conflicts of Interest

It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose any real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

FacultyRelationship Identified With:
Ian Flinn, MDNothing to disclose
Daniel D. DeAngelo, MD, PhDConsultant/Advisor: Amgen Inc, Celgene Corporation, Incyte Corporation, Novartis AG, Pfizer Inc, Shire, Takeda Pharmaceutical Company Limited
Mitchell R. Smith, MD, PhD

Consultant/Advisor: AstraZeneca, Genentech, Inc., Seattle Genetics, Inc

Speakers Bureau: Kite Pharma, Seattle Genetics, Inc

Non-faculty: Sandy Breslow; Alison Kemp; Bernard M. Abrams, MD; Cordelia Nagle; Megan Cannon; Marijke Verhaaf; hereby state that neither they nor their spouse/life partner have had any financial relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Financial Support

This activity has been supported by an independent educational grant from Amgen Inc.

Provider Information

Jointly provided by the Elsevier Office of Continuing Medical Education and Excerpta Medica.

CME Credit (Physicians)

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Elsevier Office of Continuing Medical Education and Excerpta Medica. The Elsevier Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


For all CME inquiries or special needs, please contact

Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, Excerpta Medica, and Amgen do not recommend the use of any agent outside of the labeled indications.

Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 Non-physician
Course opens: 
Course expires: 

Available Credit

  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 Non-physician
Please login or register to take this course.